The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a […]Read More
Shots: The termination of 2014 deal, is based on evaluation of portfolio and prioritization of assets within Janssen’s portfolio Janssen to support Geron involving transfer of ongoing clinical trials, regulatory, medical affairs, manufacturing and preclinical activities for 12 months and supply imetelstat for clinical manufacturing for up to 24 months Imetelstat is currently evaluated in […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
